Trestolone acetate is a synthetic androgen originally developed as a potential male contraceptive and testosterone replacement. Also known by its chemical name 7-alpha-methyl-19-nortestosterone (MENT), it was created by the Population Council, a nonprofit research organization, and has been studied in clinical trials at doses of 1 to 2 mg per day. It is not approved for prescription use in any country and remains an investigational compound.
The drug has gained attention in bodybuilding and performance-enhancement circles due to its potent androgenic and anabolic properties, but its clinical history is rooted in reproductive medicine. Understanding what trestolone actually does in the body, and how it differs from testosterone, helps explain both the research interest and the risks.
How Trestolone Works in the Body
Trestolone is structurally related to nandrolone (a well-known anabolic steroid) but with a methyl group added at the 7-alpha position. Its molecular formula is C21H30O3, with a molecular weight of about 330. The “acetate” part refers to an ester attached to the molecule that affects how quickly it’s absorbed and released after injection.
Once in the bloodstream, trestolone binds to androgen receptors, the same receptors that testosterone activates to drive muscle growth, bone density, and male sexual characteristics. It suppresses the brain’s release of two key signaling hormones: follicle-stimulating hormone (FSH) and luteinizing hormone (LH). FSH drives sperm production, while LH tells the testes to produce testosterone. By shutting down both signals, trestolone simultaneously acts as a contraceptive and replaces the androgenic functions that would otherwise be lost when natural testosterone drops.
In clinical studies, 100% of subjects developed azoospermia (zero sperm count) within 12 months of trestolone administration. This effect was reversible after the drug was discontinued, which is what made it attractive as a contraceptive candidate.
How It Differs From Testosterone
Two metabolic quirks set trestolone apart from testosterone, and both have practical consequences.
First, trestolone is resistant to 5-alpha reductase, the enzyme that converts testosterone into a more potent form called DHT. In the body, DHT is responsible for stimulating prostate growth and contributing to male pattern hair loss. Because trestolone can’t be converted to DHT, researchers initially hoped it would avoid overstimulating the prostate, making it potentially safer for long-term use in hormone replacement. However, the same resistance to 5-alpha reduction means trestolone’s androgenic effects on the skin are not reduced the way testosterone’s are in certain tissues. Some research notes this could actually increase the risk of acne and hair loss, since the parent compound itself is androgenic throughout the body without being “filtered” by tissue-specific enzymes.
Second, trestolone does aromatize, meaning the body converts it into an estrogen. The specific estrogen it produces is 7-alpha-methyl-estradiol, a metabolite that hasn’t been as extensively studied as the estradiol produced from testosterone. Aromatization is important because estrogen plays a role in bone health, cardiovascular function, and mood in men. The fact that trestolone converts to its own unique estrogen rather than standard estradiol introduces unknowns about long-term health effects.
Trestolone also binds loosely to sex hormone-binding globulin (SHBG), the protein that carries sex hormones through the blood and limits how much is available to tissues. Loose binding means a higher proportion of trestolone remains “free” and active, which contributes to its potency at low doses.
Its History as a Male Contraceptive
The Population Council developed trestolone as part of a decades-long effort to create a reversible hormonal contraceptive for men. The concept is straightforward: suppress sperm production with a progestin-like effect while maintaining enough androgenic activity to preserve libido, muscle mass, and other functions that depend on male hormones. Testosterone alone can do this, but it requires relatively high doses and doesn’t suppress sperm reliably in all men.
Trestolone showed strong suppression of sperm production in early trials, but the Population Council’s contraceptive development eventually shifted toward a different approach: a combination gel containing Nestorone (a progestin) and testosterone. That product completed a Phase 2b trial in 462 couples and is now being planned for Phase 3 trials, which would make it the first hormonal male contraceptive to reach that stage. Trestolone itself was not advanced to late-stage contraceptive trials.
Clinical Dosing vs. Performance Use
In clinical research, trestolone was studied at 1 to 2 mg per day, typically delivered through subdermal implants or intramuscular injections. At these doses, researchers observed minimal side effects and limited impact on standard blood markers. It’s worth emphasizing that trestolone has never been tested in humans at doses higher than 2 mg per day in any published clinical trial.
In underground performance-enhancement use, doses reported online are often many times higher than what was studied clinically. Because the compound was never approved or brought to market, there is no pharmaceutical-grade product, no standardized dosing, and no long-term safety data at supraphysiological doses. Users are working entirely outside the bounds of what has been tested in controlled settings.
Risks and Unknowns
The limited clinical data means several important questions remain unanswered. The long-term cardiovascular effects of trestolone are unknown. Its unique estrogen metabolite, 7-alpha-methyl-estradiol, has not been studied for chronic exposure in humans, so its effects on cholesterol, clotting, and breast tissue are not well characterized.
Like all exogenous androgens, trestolone suppresses the body’s natural testosterone production. While sperm counts recovered after discontinuation in clinical studies, the timeline and completeness of hormonal recovery at higher doses or longer durations have not been documented. Suppression of natural hormone production is a predictable consequence of any external androgen use, and recovery is not guaranteed to be smooth or complete in every individual.
The compound’s resistance to 5-alpha reductase, while potentially sparing the prostate, also means that drugs commonly used to manage androgenic side effects (like hair loss treatments that block 5-alpha reductase) would have no effect on trestolone’s activity. If you experience androgenic side effects from trestolone, the usual countermeasures don’t apply.
Current Legal and Regulatory Status
Trestolone acetate is not approved by the FDA or any other major regulatory agency for any medical use. It is not available by prescription. In the United States, it is classified as an anabolic steroid under the Controlled Substances Act, making its possession and distribution without a valid prescription illegal. It is sold through gray-market research chemical suppliers and underground labs, but these products are unregulated and carry the usual risks of contamination, mislabeling, and inconsistent dosing.